Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults

BMC Cancer

Table 4 Clinical characteristics and treatment outcomes of patients with initial CNS disease

Patient	Age (years)	Gender	FAB	Leukocyte (/μL)	Cytogenetics	CNS Symptoms	Relapse	HSCT	Outcome
1	43	F	M1	1860	CN	Seizure	Yes^#	Yes	CR in 52.7 m
2	21	F	M2	15430	t(8;21)	Blurred vision	No	Yes	CR in 41.4 m
3	60	F	M4	74390	t(9;11)(p22;q23)	Dizziness	-^∆	No	Died in 3 m
4	26	F	M4	175900	inv(16)	Headache	No	No	CR in 63.1 m
5	72	M	M4	168630	inv(16)	Dizziness	No	No	CR in 40.9 m
6	53	F	M4	93340	+8	Paresthesias	No	No	Died in 4.3 m
7	40	M	M1	277250	CN	Headache	No	No	CR in 58.1 m

^#This patient suffered from marrow relapse but not CNS relapse.
^∆This patient suffered from induction death after standard induction chemotherapy.
Abbreviation: F, female; M, male; FAB, French-American-British; CN, normal karyotype; CNS, central nervous system; HSCT, hematopoietic, stem cell transplantation; CR, complete remission; m, month.

ISSN: 1471-2407